ReviewVascular health and risk management2020

Cardiovascular Outcomes and Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: Current Data and Future Prospects.

Daniel A Duprez et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.